Medscape | Obinutuzumab Beats Rituximab in CLL Medscape The new anti-CD20 antibody obinutuzumab (Gazya) performed better than the older product rituximab (Rituxan) when both were added to chemotherapy in previously untreated patients with chronic lymphocytic leukemia (CLL) and comorbidities. North Shore-LIJ Cancer Institute doctors' editorial published |
